Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121

Phase 1KRRO-121Positive

AI Analysis

Summary

Korro Bio announced the first cohort of participants has been dosed in its Phase 1/2 clinical trial (ANCHOR) for KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide for hyperammonemia treatment in urea cycle disorder and hepatic encephalopathy patients.

Clinical Trial Data

Phase

Phase 1/2

Outcome Details

First cohort dosed in Phase 1/2 clinical trial (ANCHOR)

Importance:5/10

Sentiment:

0.60

Phase 1/2Clinical TrialOPERA platformRNA-editingRare DiseaseTrial Start

Related Companies

$KRRO

Read the original article

Published by GlobeNewswire Clinical Studies on October 5, 2026 8:05 PM

Read Original